Mesoblast Limited vs Peloton Interactive Inc — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while Peloton Interactive Inc trades at $6.43 (market cap $2.82B). The key difference: Peloton Interactive Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| MESO | PTON | |
|---|---|---|
Market Cap | $2.17B | $2.82B |
Sector | Technology | Consumer Cyclical |
52-Week High | $20.96 | $9.00 |
52-Week Low | $12.88 | $3.71 |
Enterprise Value | $2.17B | $3.42B |
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Peloton (PTON) trades at $6.545, up 6.94% today, showing stabilization after years of decline. The company achieved positive operating cash flow of $333M in 2025 and is projected to return to net profitability in 2026. Technical indicators are bullish on moving averages, while fundamentals reveal high debt levels but improving margins. Recent news highlights leadership changes and inclusion in the S&P SmallCap 600 index as potential catalysts.
Outlook remains cautious but improving; PTON offers turnaround potential with cost controls driving cash flow, but risks include persistent revenue declines and substantial long-term debt of $1.49B. Analyst consensus is mixed with a $7.50 price target, suggesting modest upside if execution continues.
Trailing returns across standard periods
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →